Novartis suspends production of 2 cancer treatments over quality concerns

Novartis is temporarily suspending production of Lutathera and Pluvicto over “potential quality issues identified in its manufacturing processes,” it said May 5. 

Read the full post on Becker's Hospital Review - Healthcare News